Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017

Doyoung Kim, Mahwesh Saleem, Bosco Paes, Ian Mitchell, Krista L Lanctôt, Doyoung Kim, Mahwesh Saleem, Bosco Paes, Ian Mitchell, Krista L Lanctôt

Abstract

Background: Infants with congenital diaphragmatic hernia (CDH) are at an increased risk of respiratory morbidity from recurrent respiratory tract infections including those from respiratory syncytial virus (RSV). Prospective studies on RSV prophylaxis in CDH infants are limited. We determined the risk of respiratory illness- and RSV-related hospitalizations (RIH and RSVH, respectively) among infants prophylaxed for CDH, standard indications (SIs) and those without increased risk (NR).

Methods: The prospective Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab (CARESS) registry was searched for infants who received palivizumab during 12 RSV seasons (2005-2017) in Canada. Cox proportional hazards analyses were conducted to compare RIH and RSVH risks across the groups adjusted for potential confounders.

Results: In total, 21 107 infants (201 CDH, 389 NR, and 20 517 SI) were included. RIH incidences were 10.0% (CDH), 2.1% (NR), and 6.2% (SI). CDH patients had a significantly higher RIH hazard compared with NR (hazard ratio [HR], 3.6 [95% confidence interval {CI}, 1.5-8.8]; P = .005) but not SI (HR, 1.2 [95% CI, .8-2.0]; P = .379). RSVH incidences were 0.6%, 0.3%, and 1.5% for CDH, NR, and SI, respectively. RSVH risk was similar across groups (SI: HR, 0.0, P = .922; NR: HR, 0.0, P = .934).

Conclusions: CDH infants had a 3-fold increased risk of RIH compared to NR but not SI infants. RSVH risk was similar with low RSVH incidences across all groups, implying that CDH infants may benefit from palivizumab during the RSV season, similar to other high-risk groups.

Clinical trials registration: NCT00420966.

Keywords: RSV; congenital diaphragmatic hernia; outcome; palivizumab; respiratory syncytial virus.

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Cox proportional hazards analysis of respiratory illness–related hospitalizations. CDH vs NR: hazard ratio (HR), 3.6 (95% confidence interval [CI], 1.5–8.8; P = .005); CDH vs SI: HR, 1.2 (95% CI, 0.8–2.0; P = .379). Analysis was adjusted for appropriate demographic variables (see Table 1). Abbreviations: CDH, congenital diaphragmatic hernia; NR, not at increased risk; SI, standard indication.
Figure 2.
Figure 2.
Cox proportional hazards analysis of respiratory syncytial virus–related hospitalization. CDH vs SI: hazard ratio (HR), 0.0; P = .922. CDH vs NR: HR, 0.0; P = .934. Analysis was adjusted for appropriate demographic variables (see Table 1). Abbreviations: CDH, congenital diaphragmatic hernia; NR, not at increased risk; SI, standard indication.

References

    1. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol 2008; 82:2040–55.
    1. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003; 143:S150–6.
    1. Bont L, Checchia PA, Fauroux B, et al. . Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in Western countries. Infect Dis Ther 2016; 5:271–98.
    1. Fauroux B, Simões EAF, Checchia PA, et al. . The burden and long-term respiratory morbidity associated with respiratory syncytial virus infection in early childhood. Infect Dis Ther 2017; 6:173–97.
    1. Manzoni P, Paes B, Resch B, et al. . High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention. Early Hum Dev 2012; 88(Suppl 2):S34–41.
    1. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134:415–20.
    1. Robinson JL, Le Saux N; Canadian Paediatric Society, Infectious Diseases and Immunization Committee Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health 2015; 20:321–33.
    1. Gabra HOS, Wilkinson DJ, Losty PD. Management of congenital diaphragmatic hernia. Paediatr Child Health 2018; 28:18–21.
    1. Russo FM, De Coppi P, Allegaert K, et al. . Current and future antenatal management of isolated congenital diaphragmatic hernia. Semin Fetal Neonatal Med 2017; 22:383–90.
    1. Ameis D, Khoshgoo N, Keijzer R. Abnormal lung development in congenital diaphragmatic hernia. Semin Pediatr Surg 2017; 26:123–8.
    1. Bagolan P, Morini F. Long-term follow up of infants with congenital diaphragmatic hernia. Semin Pediatr Surg 2007; 16:134–44.
    1. Masumoto K, Nagata K, Uesugi T, et al. . Risk of respiratory syncytial virus in survivors with severe congenital diaphragmatic hernia. Pediatr Int 2008; 50:459–63.
    1. Kamata S, Usui N, Kamiyama M, et al. . Long-term follow-up of patients with high-risk congenital diaphragmatic hernia. J Pediatr Surg 2005; 40:1833–8.
    1. Resch B, Liziczai K, Reiterer F, Freidl T, Haim M, Urlesberger B. Respiratory syncytial virus associated hospitalizations in children with congenital diaphragmatic hernia. Pediatr Neonatol 2018; 59:184–8.
    1. Gischler SJ, van der Cammen-van Zijp MH, Mazer P, et al. . A prospective comparative evaluation of persistent respiratory morbidity in esophageal atresia and congenital diaphragmatic hernia survivors. J Pediatr Surg 2009; 44:1683–90.
    1. Koziarkiewicz M, Taczalska A, Piaseczna-Piotrowska A. Long-term follow-up of children with congenital diaphragmatic hernia—observations from a single institution. Eur J Pediatr Surg 2014; 24:500–7.
    1. Muratore CS, Kharasch V, Lund DP, et al. . Pulmonary morbidity in 100 survivors of congenital diaphragmatic hernia monitored in a multidisciplinary clinic. J Pediatr Surg 2001; 36:133–40.
    1. Bollani L, Baraldi E, Chirico G, et al. . Italian Society of Neonatology Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr 2015; 41:97.
    1. Dotan M, Ashkenazi-Hoffnung L, Samra Z, et al. . Hospitalization for respiratory syncytial virus bronchiolitis and disease severity in twins. Isr Med Assoc J 2013; 15:701–4.
    1. Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL; CARESS Investigators Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian registry of palivizumab. Pediatr Infect Dis J 2015; 34:e290–7.
    1. Peetsold MG, Heij HA, Kneepkens CM, Nagelkerke AF, Huisman J, Gemke RJ. The long-term follow-up of patients with a congenital diaphragmatic hernia: a broad spectrum of morbidity. Pediatr Surg Int 2009; 25:1–17.
    1. Wischermann A, Holschneider AM, Hübner U. Long-term follow-up of children with diaphragmatic hernia. Eur J Pediatr Surg 1995; 5:13–8.
    1. American Academy of Pediatrics Section on Surgery, American Academy of Pediatrics Committee on Fetus and Newborn; Lally KP, Engle W. Postdischarge follow-up of infants with congenital diaphragmatic hernia. Pediatrics 2008; 121:627–32.
    1. Kristensen K, Hjuler T, Ravn H, Simões EA, Stensballe LG. Chronic diseases, chromosomal abnormalities, and congenital malformations as risk factors for respiratory syncytial virus hospitalization: a population-based cohort study. Clin Infect Dis 2012; 54:810–7.
    1. Helfrich AM, Nylund CM, Eberly MD, Eide MB, Stagliano DR. Healthy late-preterm infants born 33-36 + 6 weeks gestational age have higher risk for respiratory syncytial virus hospitalization. Early Hum Dev 2015; 91:541–6.
    1. Eriksson M, Bennet R, Rotzén-Ostlund M, von Sydow M, Wirgart BZ. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr 2002; 91:593–8.
    1. Gouyon JB, Rozé JC, Guillermet-Fromentin C, et al. . Hospitalizations for respiratory syncytial virus bronchiolitis in preterm infants at <33 weeks gestation without bronchopulmonary dysplasia: the CASTOR study. Epidemiol Infect 2013; 141:816–26.
    1. Gijtenbeek RG, Kerstjens JM, Reijneveld SA, Duiverman EJ, Bos AF, Vrijlandt EJ. RSV infection among children born moderately preterm in a community-based cohort. Eur J Pediatr 2015; 174:435–42.
    1. Hall CB, Weinberg GA, Blumkin AK, et al. . Respiratory syncytial virus–associated hospitalizations among children less than 24 months of age. Pediatrics 2013; 132:e341–8.
    1. O’Brien KL, Chandran A, Weatherholtz R, et al. . Respiratory Syncytial Virus (RSV) Prevention Study Group Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis 2015; 15:1398–408.
    1. Gaboli M, de la Cruz ÒA, de Agüero MI, Moreno-Galdó A, Pérez GP, de Querol MS. Use of palivizumab in infants and young children with severe respiratory disease: a Delphi study. Pediatr Pulmonol 2014; 49:490–502.
    1. Coughlin MA, Werner NL, Gajarski R, et al. . Prenatally diagnosed severe CDH: mortality and morbidity remain high. J Pediatr Surg 2016; 51:1091–5.
    1. Lakshminrusimha S, Keszler M, Kirpalani H, et al. . Milrinone in congenital diaphragmatic hernia—a randomized pilot trial: study protocol, review of literature and survey of current practices. Matern Health Neonatol Perinatol 2017; 3:27.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir